The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Open accessAbstract
BACKGROUND: Adjuvant tamoxifen therapy substantially decreases the risk of recurrence and mortality in women with hormone (estrogen and/or progesterone) receptor-positive breast cancer. Previous studies have suggested that metabolic conversion of tamoxifen to endoxifen by cytochrome P450 2D6 (CYP2D6) is required for patient benefit from tamoxifen therapy. METHODS: Tumor specimens from a subset of postmenopausal patients with hormone receptor-positive early-stage (stages I, II, and IIIA) breast cancer, who were enrolled in the randomized double-blind Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial, were genotyped for variants in CYP2D6 (N = 1203 patients: anastrozole [trade name: Arimidex] group, n = 615 patients; tamoxifen group, n = 588 patients) and UDP-glucuronosyltransferase-2B7 (UGT2B7), whose gene product inactivates endoxifen (N = 1209 patients; anastrozole group, n = 606 patients; tamoxifen group, n = 603 patients). Genotyping was performed using polymerase chain reaction-based TaqMan assays. Based on the genotypes for CYP2D6, patients were classified as poor metabolizer (PM), intermediate metabolizer (IM), or extensive metabolizer (EM) phenotypes. We evaluated the association of CYP2D6 and UGT2B7 genotype with distant recurrence (primary endpoint) and any recurrence (secondary endpoint) by estimating the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) using Cox proportional hazards models. All statistical tests were two-sided. RESULTS: After a median follow-up of 10 years, no statistically significant associations were observed between CYP2D6 genotype and recurrence in tamoxifen-treated patients (PM vs EM: HR for distant recurrence = 1.25, 95% CI = 0.55 to 3.15, P = .64; HR for any recurrence = 0.99, 95% CI = 0.48 to 2.08, P = .99). A near-null association was observed between UGT2B7 genotype and recurrence in tamoxifen-treated patients. No associations were observed between CYP2D6 and UGT2B7 genotypes and recurrence in anastrozole-treated patients. CONCLUSION: The results do not support the hypothesis that CYP2D6 genotype predicts clinical benefit of adjuvant tamoxifen treatment among postmenopausal breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Self-citationUse of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,037
Self-citationJin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Self-citation(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Self-citationGoetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Self-citationThe CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Self-citationDowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
Self-citationRegan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Self-citationFallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.029 · Cited by 310
Self-citationWegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B., & Wingren, S. (2007) · Breast Cancer Research · doi:10.1186/bcr1640 · Cited by 288
Bhasker, C. R., McKinnon, W., Stone, A., Lo, A. C., Kubota, T., Ishizaki, T., & Miners, J. O. (2000) · Pharmacogenetics · doi:10.1097/00008571-200011000-00002 · Cited by 245
Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response
Goetz, M. P., Kamal, A., & Ames, M. M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100367 · Cited by 193
Cuzick, J., Sestak, I., Cella, D., & Fallowfield, L. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70259-6 · Cited by 185
Self-citationOntogeny of Dextromethorphan O- and N-demethylation in the First Year of Life
Blake, M. J., Gaedigk, A., Pearce, R. E., Bomgaars, L. R., Christensen, M. L., Stowe, C., James, L. P., Wilson, J. T., Kearns, G. L., & Leeder, J. S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100101 · Cited by 169
Ravdin, P., Fritz, N. F., Tormey, D. C., & Jordan, V. C. (1988) · PubMed · Cited by 122
CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
Lash, T. L., Cronin-Fenton, D. P., Ahern, T. P., Rosenberg, C. L., Lunetta, K. L., Silliman, R. A., Garne, J. P., Sørensen, H. T., Hellberg, Y., Christensen, M., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr010 · Cited by 103
Punglia, R. S., Burstein, H. J., Winer, E. P., & Weeks, J. C. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn100 · Cited by 95
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A., Desta, Z., Storniolo, A. M., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.14 · Cited by 93
Self-citationDowsett, M., & Haynes, B. P. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00365-0 · Cited by 88
Self-citationHayes, D. F., Stearns, V., Rae, J. M., & Flockhart, D. A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn271 · Cited by 84
Self-citationIn vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
Kamdem, L. K., Liu, Y., Stearns, V., Kadlubar, S. A., Ramı́rez, J., Jeter, S. C., Shahverdi, K., Ward, B. A., Ogburn, E. T., Ratain, M. J., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03791.x · Cited by 81
Self-citationCytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
Šeruga, B., & Amir, E. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0902-3 · Cited by 40
Hayes, D. F., Stearns, V., Rae, J. M., & Flockhart, D. A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn127 · Cited by 35
Self-citationClinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes
Cronin-Fenton, D. P., & Lash, T. L. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.18 · Cited by 27
Pharmacogenomics of Tamoxifen in a Nutshell--And Who Broke the Nutcracker?
Holmes, F. A., & Liticker, J. D. (2005) · Journal of Oncology Practice · doi:10.1200/jop.2005.1.4.155 · Cited by 14
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“, 2012), other studies found no (Rae et al., 2012; Regan et al., 2012) or inconsistent allele-specific effects (Abraham et al.”
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Self-citationChen, M. S., Lara, P. N., Dang, J. H. T., Paterniti, D. A., & Kelly, K. (2014) · Cancer · doi:10.1002/cncr.28575 · Cited by 472
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Self-citation
Metadata
- Authors
- Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Sestak, I., Cuzick, J., & Dowsett, M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-06
- Volume
- 104
- Issue
- 6
- Pages
- 452-460
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2120384798
- Cited by
- 259
- References
- 43
- FWCI
- 44.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.